Vastned Belgium publishes the agenda for the ordinary general meeting of shareholders of April 27, 2022
Vastned Belgium today publishes the convocation and agenda for the ordinary general meeting of shareholders to be held on Wednesday 27 April 2021 at 2.30 pm.
Full press release:
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Vallourec first quarter 2022 results - New initiatives launched to be cycle-proof18.5.2022 18:15:00 CEST | Press release
Meudon (France), May 18, 2022 Vallourec first quarter 2022 results New initiativeslaunched to be cycle-proof Q1 2022 results in line with expectations €916 million revenue, a 30% year-over-year increase led by North America€45 million reported EBITDA negatively impacted by the iron ore mine shutdown; normalized level of ~€130 million1€(230) million Free Cash Flow impacted by €(217) million working capital build-up reflecting higher forward volume expectations and raw material price increases FY 2022 EBITDA now expected to be significantly above 2021, despite Q1 impacted by mine shutdown €230million of recurring EBITDA and €250million ongoing cash up-lift (+€100million compared to November 2021 announcement) Launching the closure process of German sites and refocusing European plantsStreamline corporate structure to better manage a reshaped industrial footprint and a leaner organization Philippe Guillemot, Chairman of the Board of Directors and Chief Executive Officer, declared: “Steppi
Changes in financial results publication18.5.2022 18:01:16 CEST | Press release
PRFoods AS declares that 2021/2022 financial year 9 months unaudited results will be published, according to Stock Exchange rules no later than two months after end of the reporting period, 31.5.2022. Although interim report will be unaudited, PRFoods has required a third party assessment of the impact of sale of Heimon Kala Oy, taking into account that final purchase price is dependent on certain conditions subsequent presumed to be met before publication. Indrek Kasela AS PRFoods Member of the Management Board Phone: +372 452 1470 email@example.com www.prfoods.ee
PRESS RELEASE: NACON: WRC GENERATIONS: THE MOST COMPLETE RALLY GAME IS COMING IN OCTOBER!18.5.2022 17:46:00 CEST | Press release
WRC GENERATIONS: THE MOST COMPLETE RALLY GAME IS COMING IN OCTOBER! Lesquin, 18th May 2022 - NACON and the studio KT Racing are pleased to announce their new rally game, WRC Generations, the official video game of the FIA World Rally Championship, scheduled for release in Autumn 2022 on PlayStation®4, PlayStation®5, Xbox One, Xbox Series X|S, Nintendo Switch and Steam for PC. The result of 7 years of collaboration with legendary drivers, who have already made WRC 10 and WRC 9 the references of the genre, the latest entry in the series is an authentic and comprehensive rally racing simulation, giving players the chance to drive powerful cars in the most famous rallies of all time! Check out the announcement trailer for WRC Generations: [link] An unrivalled level of realism Never before have games come this close to the real-life World Rally Championship! Hailed by both critics and professionals, this year's WRC simulation has been reinforced with numerous improvements and optimisations
PRESS RELEASE: NACON PRESENTS AN AMBITIOUS LINEUP AND ANNOUNCES TWO NEW GAMES18.5.2022 17:45:00 CEST | Press release
NACON PRESENTS AN AMBITIOUS LINEUP AND ANNOUNCES TWO NEW GAMES NACON has confirmed its status as a major mid-publisher and creator of standard-setting accessories Paris (France), 18 May 2022 – The latest edition of Bigben Week opened its doors on Monday. This major event for the group is the perfect occasion to present its products and objectives to the media and international partners. NACON, the group's gaming brand, held a press conference to announce all of its news and to explain how it is changing. The last time the event was held – in 2019, due to the health crisis – BIGBEN presented its soaring ambitions for the years to come. Bigben Week is an opportunity to highlight the company's strong growth over the last three years along with the major changes it has undergone. AN EFFECTIVE STRATEGY NACON’s March 2020 listing on the stock market raised more than €100 million, reinforcing the company's ambitions and resources. Over the course of three years, NACON acquired no fewer than 9
FDA beviljar särläkemedelsstatus för tasquinimod vid behandling av myelofibros18.5.2022 15:00:00 CEST | Pressemelding
Lund 18 maj 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) meddelade idag att amerikanska Food and Drug Administration (FDA) har beviljat särläkemedelsstatus för tasquinimod vid behandling av myelofibros. "Särläkemedelsstatus som FDA tilldelat för tasquinimod i myelofibros utgör ett viktigt steg framåt för Active Biotech", säger Helén Tuvesson, VD Active Biotech. "Det öppnar en viktig regulatorisk väg och ger oss potential att snabbt avancera utvecklingen av tasquinimod i denna patientpopulation.” FDAs Orphan Drug Designation program ger särläkemedelsstatus för läkemedelskandidater avsedda för säker och effektiv behandling, diagnos eller förebyggande av ovanliga sjukdomar som drabbar färre än 200.000 människor i USA. Denna särläkemedelsstatus ger 7 års marknadsexklusivitet vid marknadsgodkännande samt vissa andra fördelar. I februari 2022 ingick Active Biotech ett exklusivt licensavtal med Oncode Institute i Nederländerna, som verkar på uppdrag av Erasmus University Medical Center (